<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Connolly, Stuart J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Apixaban Reduces Stroke Risk in Patients with AF: Results from the AVERROES Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">The oral direct factor Xa inhibitor apixaban was superior to aspirin therapy for the reduction of stroke or systemic embolism risk in patients with atrial fibrillation who were unsuitable for vitamin K antagonist therapy according to the phase III Apixaban versus Acetylsalicylic Acid to Prevent Strokes [AVERROES; NCT00496769] trial.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>